Dependence on customer program success
Teknova sells inputs to customers whose own products must win regulatory approval and market acceptance.
- Scope
- Pharmaceutical, biotech, and diagnostics end markets
- Materiality
- high
Alpha Teknova, Inc.
Alpha Teknova makes custom and catalog reagents used to discover, develop, and commercialize therapies, vaccines, and molecular diagnostics. Its products are designed for life sciences customers that need high-quality, made-to-order formulations with short turnaround times and consistent manufacturing at scale. The company serves more than 3,000 customers across pharmaceutical and biotechnology companies, CDMOs, diagnostics franchises, and academic and government labs. Teknova’s business is built around configurable manufacturing processes and quality systems that support customers from early research through GMP and commercialization.
−26,2 %
33,2 %
−42,6 %
+7,4 %
4.58
3.64
| % | |
|---|---|
| Custom critical reagents | 55% Customer-specified reagent formulations made to order for research, development, and commercialization workflows. |
| Catalog RUO products | 25% Standard research-use-only reagents sold from the company’s catalog for routine life sciences applications. |
| GMP-grade reagents | 10% Manufactured reagents used in regulated development and production environments for therapeutic programs. |
| Molecular diagnostics reagents | 5% Reagents and formulations used by diagnostics customers in assay development and commercialization. |
| Other life sciences reagents and services | 5% Adjacencies such as specialized formulations, support services, and smaller product lines. |
Teknova sells into the full life sciences development chain, so its customers include early-stage research labs as well...
- Pharmaceutical and biotechnology companiesprimary
Buy custom and GMP-grade reagents for discovery, development, and commercialization of therapeutic programs.
- Contract development and manufacturing organizationsprimary
Purchase reliable reagent inputs for client projects where consistency, scale, and turnaround time matter.
- In vitro diagnostics franchisessecondary
Use Teknova formulations in assay development and commercialization for molecular diagnostics.
- Academic and government research institutionssecondary
Buy catalog RUO products and custom reagents for research workflows and grant-funded projects.
- Cell and gene therapy developersprimary
Need specialized reagents for high-growth therapeutic development and manufacturing workflows.
Teknova is heavily concentrated in the United States, where 94.4% of 2025 revenue came from U.S. customers...
- •United States accounted for 94.4% of 2025 revenue
- •International revenue was 5.6% of 2025 revenue
- •International sales were mainly from the United Kingdom, Canada, and Singapore
- •Management sees Europe as a key expansion market
- •Hollister, California is the principal operating and manufacturing base
- •Geographic expansion depends on distributors, local manufacturing, or acquisitions
Teknova’s strategy centers on operational excellence: investing in automation, facilities, and manufacturing...
01
Operational excellence and capacity expansionshort-term
Fast, reliable custom manufacturing is the core competitive advantage and supports repeat business.
02
Customer retention and workflow embedmentmedium-term
Products that become embedded in customer processes create recurring demand and switching costs.
03
International expansion, especially Europemedium-term
The company is highly U.S.-concentrated and sees overseas markets as a long-term growth lever.
Teknova remains exposed to operating losses, competitive pressure, and the cyclicality of biotech and diagnostics...
Operating losses and financing needs
The company has incurred losses and may need continued capital to fund operations and expansion.
- Scope
- Liquidity and growth investment
- Materiality
- high
Manufacturing and supply chain disruption
Short turnaround times and quality consistency are core to the business, so any disruption can affect delivery and retention.
- Scope
- Facilities, suppliers, and logistics
- Materiality
- high
Competitive pressure and in-house substitution
Customers may choose larger competitors or produce similar reagents internally if it is cheaper or more convenient.
- Scope
- Custom reagents and RUO products
- Materiality
- high
Cybersecurity incident
A breach could interrupt operations, impair systems, or damage reputation and customer trust.
- Scope
- Internal systems and third-party data environments
- Materiality
- medium
International expansion and acquisition execution
Entering new markets or integrating acquisitions can create operational and financial complexity without guaranteed payoff.
- Scope
- Europe and adjacent markets
- Materiality
- medium
Revenue recognition for custom orders
Can shift revenue timing between periods
Inventory valuation and obsolescence
Affects cost of sales and gross margin
Lease accounting
Affects balance sheet leverage and fixed-cost visibility
Stock-based compensation
Affects operating income and earnings comparability
AstroNova, Inc.
ALOT · Computer Peripheral Equipment, NEC
Innoviva, Inc.
INVA · Pharmaceutical Preparations
IQVIA HOLDINGS INC.
IQV · Services-Commercial Physical & Biological Research
RenovoRx, Inc.
RNXT · Pharmaceutical Preparations
HOOKIPA Pharma Inc.
HOOK · Pharmaceutical Preparations
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
: 11/08/2026